924909-17-1

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]pyridine, 4-chloro-1-[(4-Methoxyphenyl)Methyl]-
• Synonyms: 1H-Pyrazolo[3,4-b]pyridine, 4-chloro-1-[(4-Methoxyphenyl)Methyl]-;4-chloro-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine
• CAS NO: 924909-17-1
• Molecular Formula: C₁₄H₁₂ClN₃O
• Molecular Weight: 273.71758
• Mol File: 924909-17-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]pyridine, 4-chloro-1-[(4-Methoxyphenyl)Methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]pyridine, 4-chloro-1-[(4-Methoxyphenyl)Methyl]-(924909-17-1)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]pyridine, 4-chloro-1-[(4-Methoxyphenyl)Methyl]-(924909-17-1)

Safety Data

• Hazardous Substances Data: 924909-17-1(Hazardous Substances Data)

Usage

Structure

Pyrazolopyridine derivative with a chloro group and a (4-methoxyphenyl)methyl substituent

Pharmaceutical applications

Potential use in the development of new drugs with therapeutic properties such as anti-inflammatory, analgesic, or antitumor activities

Synthesis

May be used as an intermediate in the synthesis of various organic compounds

Upstream product

• 924909-16-0 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol 
• 3528-45-8 1-(4-methoxybenzyl)-1H-pyrazol-5-amine 
• 949556-46-1 5-(((1-(4-methoxybenzyl)-1H-pyrazol-5-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 123-11-5 4-methoxy-benzaldehyde 
• 227617-15-4 4-Hydroxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 370865-99-9 4-Hydroxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 227617-24-5 2-(4-methoxy-benzyl)-2H-pyrazol-3-yl-amine monohydrochloride 

Downstream Products

• 29274-28-0 4-Chloro-1H-pyrazolo<3,4-b>pyridine 
• 924909-18-2 4-[1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy]aniline 
• 1357945-38-0 3-bromo-4-chloro-1H-pyrazolo[3,4-b]pyridine 
• 949558-30-9 4-chloro-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 949558-31-0 4-chloro-3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3 ,4-b]pyridine 

Relevant articles and documents

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS

The present invention relates to compounds according to Formulas I, IA or IB: to pharmaceutically acceptable composition, salts thereof, their synthesis and their use as SIK2 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such as cancer, stroke, cardiovascular, obesity and type II diabetes.

MULTIKINASE INHIBITOR

It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents -(O)n-R; R represents a C1-C6 alkyl group or the like; n represents 0 or 1; X represents O or the like; R2, R3 and R4 are independently selected from a hydrogen atom or C1-C3 alkyl; or R2 and R3 may join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.